Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020696 · ClinicalTrials.gov registry record · Phase 2
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00020696: Completed Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00020696 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020696, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining tirapazamine with cisplatin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
Interventions
- DRUG cisplatin
- DRUG tirapazamine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Phase | Phase 2 |
What the finished NCT00020696 record still lists
NCT00020696 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00020696 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00020696 about?
NCT00020696 is a clinical study titled "Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining tirapazamine with cisplatin in treating patients who have r...
What is the current status of trial NCT00020696?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-06.
What interventions are being tested in trial NCT00020696?
The interventions under investigation include: cisplatin (DRUG), tirapazamine (DRUG).
Who is sponsoring clinical trial NCT00020696?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia